Type 2 Diabetes Therapeutics Market Study To 2020 - According To Radiant Insights

@vasu123 (143)
United States
February 23, 2015 4:58am CST
Summary GBI Research, the leading business intelligence provider, has released its latest research, "Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth", which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts. In 2013, the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodium Glucose Transporter-2 (SGLT-2) inhibitors, as well as the growth of the prevalence population in the APAC region, particularly in India and China. Scope The report analyzes the treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals of the type 2 diabetes in the APAC markets of China, India, Japan, and Australia.It includes - - A brief introduction to type 2 diabetes, including its pathophysiology, etiology, diagnosis and treatment algorithms - In-depth analysis of currently marketed drugs for type 2 diabetes, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy - A comprehensive review of the pipeline for type 2 diabetes, including individual analysis of a number of late -stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed by Phase distribution, molecule type, program type, mechanism of action and molecular target About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. For More Information Visit – http://www.radiantinsights.com/ Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com
Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth - Radiant Insights
No responses